NanoViricides says NV-387 candidates expected to work against Congo Bundibugyo Ebola strain

NanoViricides, Inc.

NanoViricides, Inc.

NNVC

0.00
  • NanoViricides management told an Alliance Global Partners healthcare showcase on May 20, 2026 that it expects NV-387 to be effective against the Bundibugyo Ebola strain circulating in the Democratic Republic of Congo.
  • Executive Chairman Anil R. Diwan also pointed to a back-up candidate that encapsulates remdesivir in NV-387 micelles, positioning it as a potential oral formulation designed to protect remdesivir from rapid metabolism in the bloodstream.
  • Diwan said NV-387 is entering a Phase II trial against mpox in the DRC, adding that the company already has a clinical site in the country that could support any next steps if public health responders decide to proceed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-064754), on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.